COVID 19 Antibodies for IgG, IgA, and IgM - KSL Chemiluminescence Assay

GTR Test IDHelpEach Test is a specific, orderable test from a particular laboratory, and is assigned a unique GTR accession number. The format is GTR00000001.1, with a leading prefix 'GTR' followed by 8 digits, a period, then 1 or more digits representing the version. When a laboratory updates a registered test, a new version number is assigned.: GTR000593853.1
Last updated: 2021-08-25
Annual Review past due read more
Test version history
- 593853.1, last updated: 2021-08-25

Clinical microbial testHelpIn the U.S., clinical tests must be performed under CLIA certification. When a lab uses the same methods for a test in both clinical and research settings, the test appears as two separate GTR records. for COVID-19
Offered by KSL Diagnostics

Interpretation

Not provided

Comments about the test interpretation (e.g. clinical implication of test results)

Positive results to antibodies against SARS-CoV-2 are generally indicative of an individual’s current or prior infection with the SARS-Cov-2 virus. However, the duration of these antibodies remaining in circulation has not yet been established. These test results should always be considered in the context of a patient’s clinical history, physical examination, epidemiologic exposures, and vaccination history before making the final diagnosis. IgM isotype antibodies develop within 5 to 7 days indicating recent exposure to the virus. IgG isotype antibodies develop after 10 days and remain in circulation longer. It may indicate past exposure or vaccine mediated immune response. IgA isotype antibody development is variable in its response and may indicate past exposure or vaccine-mediated immune response.

Research

Is research allowed on the sample after clinical testing is complete?HelpAfter clinical testing is complete, does the laboratory perform any research testing using the submitted specimen? (Quality control is not considered as research for this question.): Not provided

Reviews

Clinical resources

Practice guidelines

NICE, 2024
UK NICE Guideline NG191, COVID-19 rapid guideline: managing COVID-19, 2024

Consumer resources

MedlinePlus

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.